Praxis Precision Medicines (PRAX) Current Deferred Revenue (2022 - 2024)

Praxis Precision Medicines' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $1.2 million for Q3 2024.

• On a quarterly basis, Current Deferred Revenue fell 24.61% year-over-year to $1.2 million in Q3 2024; TTM through Sep 2024 was $1.2 million, a 24.61% decrease from a year earlier, with the FY2023 full-year figure at $1.4 million, down 72.16% from the prior year.
• Current Deferred Revenue fell to $1.2 million in Q3 2024 per PRAX's latest filing, from $1.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $5.0 million in Q4 2022 and bottomed at $1.2 million in Q3 2024.
• The 3-year median for Current Deferred Revenue is $1.5 million (2023), against an average of $2.0 million.
• Across the five-year window, Current Deferred Revenue slumped 72.16% in 2023 and declined 24.61% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $5.0 million in 2022, then slumped by 72.16% to $1.4 million in 2023, then slipped by 15.95% to $1.2 million in 2024.
• Per Business Quant, the three latest PRAX Current Deferred Revenue figures stand at $1.2 million (Q3 2024), $1.2 million (Q2 2024), and $1.3 million (Q1 2024).